Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 11:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2737–2760 of 14,763 matching trials from the live ClinicalTrials.gov search.
Conditions
Carcinoma, Small Cell Lung
Interventions
RRx-001 + eLOOP Device, Cisplatin/carboplatin plus etoposide
Combination Product · Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
18
States / cities
Denver, Colorado • Orange City, Florida • Orlando, Florida + 15 more
Conditions
Pulmonary Arterial Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Jacksonville, Florida • Weston, Florida
Conditions
Healthy Study Participants, Participants With Mild Asthma
Interventions
Alprazolam, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
North Dartmouth, Massachusetts • Raleigh, North Carolina
Conditions
Asthma
Interventions
FF/UMEC/VI (100/31.25/25) mcg, FF/UMEC/VI (100/62.5/25) mcg, FF/UMEC/VI (200/31.25/25) mcg, FF/UMEC/VI (200/62.5/25) mcg, FF/VI (100/25) mcg, FF/VI (200/25) mcg, Fluticasone/salmeterol (FSC), Albuterol/salbutamol, ELLIPTA DPI, DISKUS DPI, METERED-DOSE INHALER (MDI)
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
99
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more
Conditions
Cystic Fibrosis
Interventions
Exercise Intervention
Behavioral
Lead sponsor
Wuerzburg University Hospital
Other
Eligibility
12 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Azithromycin, HP xenon (¹²⁹XE)
Drug · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
40 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Durham, North Carolina • Charlottesville, Virginia
Conditions
Dyspnea, Lung Cancer (Diagnosis)
Interventions
INSPIRE
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Asthma
Interventions
School-Based Supervised Asthma Therapy
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
6 Years to 12 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Lung Cancer
Interventions
6-hydroxymethylacylfulvene
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
48
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 28 more
Recruiting No phase listed Observational

UNC Pleural Fluid Registry

NCT05620329
Conditions
Lung Cancer, Lung Infection, Breast Cancer, Malignant Pleural Effusion, Empyema
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2050
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Carcinoma, Non-small-Cell Lung
Interventions
JNJ-86974680, Cetrelimab, Radiation Therapy
Drug · Radiation
Lead sponsor
Johnson & Johnson Enterprise Innovation Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Newnan, Georgia • Hackensack, New Jersey • Buffalo, New York + 4 more
Conditions
Asthma
Interventions
Symbicort pMDI, Budesonide pMDI
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 11 Years
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
59
States / cities
Hoover, Alabama • Montgomery, Alabama • Gilbert, Arizona + 56 more
Conditions
COVID-19 Pandemic, Health Knowledge, Attitudes, Practice, Perinatal Depression, Mental Health Wellness, Post Partum Depression
Interventions
Baby2Home Mobile Application
Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Chicago, Illinois • Providence, Rhode Island
Conditions
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Interventions
Pharmacokinetic sampling, AZD9291, Itraconazole
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
2
States / cities
San Diego, California • Cleveland, Ohio
Conditions
Heart Failure, Pulmonary Disease, Cancer
Interventions
Preparation and life completion, Attention Control
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
COPD
Interventions
BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg, BFF MDI 320/9.6 μg
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
64
States / cities
Dothan, Alabama • Jasper, Alabama • Peoria, Arizona + 56 more
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Aurora A Kinase Inhibitor LY3295668, Osimertinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 2 Interventional Results available

TG4010 and Nivolumab in Patients With Lung Cancer

NCT02823990
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
TG4010, Nivolumab
Biological
Lead sponsor
Megan Daly, MD
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Duarte, California • Sacramento, California • San Diego, California + 1 more
Conditions
COVID-19
Interventions
Experimental: Primary Cohort, Placebo Comparator: Primary Cohort - Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Small Cell Lung Cancer Recurrent
Interventions
Debio 0123, Etoposide, Carboplatin
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Completed Not applicable Interventional Accepts healthy volunteers Results available

KanSurvive: Testing a Model for Improving Cancer Survivorship Care in Rural Practice

NCT04763824
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Interventions
KanSurvive ECHO and Practice Facilitation
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Westwood, Kansas
Conditions
Sepsis, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Artifical Intelligence-Generated Treatment Recommendations
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Cystic Fibrosis
Interventions
VNZ/TEZ/D-IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
25 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Woburn, Massachusetts
Terminated Phase 2 Interventional Results available

Malignant Pleural Effusion With ZD6474

NCT00402896
Conditions
Lung Cancer, Pleural Effusion
Interventions
ZD6474
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Houston, Texas